Publication | Closed Access
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
830
Citations
18
References
2023
Year
In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1